Berhane Seyoum, MD
Endocrinology, Diabetes & Metabolism · Detroit, MINPI 1699702241
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,660 of the $10,543 with a category attached, or 72.6%. 40 manufacturers reported payments, led by Medtronic at 50.1% of the total. Reporting peaked in 2022 at $3,066 and has fallen 51.5% since, to $1,488 in 2025.
Across 307 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Amgen$1K
- Novo Nordisk$844
- Lilly USA, LLC$663
- Corcept Therapeutics$368
- Xeris Pharmaceuticals, Inc.$211
- plus $2K from 34 others
What the payments were for
- Consulting fees$1501%
- Travel & lodging$2,65925%
- Food & beverage$7,66073%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,838
- MINIMED 780G$1,306
- Ozempic$369
- Korlym$239
- TEPEZZA$235
- PNEUMOVAX 23$150
- TZIELD$131
- INPEN SMART INSULIN DELIVERY SYSTEM$128
- ZEPBOUND$125
- Kerendia$121
- Minimed 670G System$114
- GUARDIAN SENSOR (3)$112
How this compares
$10,543 in reported general payments places this provider in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 587 | $745,650 |
| TrulicityDulaglutide | 497 | $574,850 |
| JardianceEmpagliflozin | 466 | $451,806 |
| FarxigaDapagliflozin Propanediol | 312 | $280,853 |
| MounjaroTirzepatide | 116 | $159,720 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 319 | $87,808 |
| JanuviaSitagliptin Phosphate | 72 | $73,773 |
| TradjentaLinagliptin | 69 | $55,057 |
| FiaspInsulin Aspart (Niacinamide) | 24 | $46,056 |
| RybelsusSemaglutide | 33 | $42,723 |
| ProliaDenosumab | 24 | $41,033 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 115 | $37,646 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 128 | $19,681 |
| NovologInsulin Aspart | 60 | $18,454 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $16,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog, Novolog Mix 70-30 | $844 | $856,006722 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog | $663 | $747,094650 claims |
| Boehringer IngelheimJardiance, Tradjenta | $65 | $506,863535 claims |
| AstraZenecaFarxiga | $132 | $280,853312 claims |
| AmgenProlia | $1,072 | $41,03324 claims |
| Sanofi-aventis U.S. LLCAdmelog | $187 | $4,46215 claims |
| AbbVieSynthroid | $24 | $3,34038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Detroit
- Henry BoneDetroit$120K
- Shobana AthimulamDetroit$14K
- Wael TahaDetroit$12K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.